Advantage Investment Management’s Agios Pharmaceuticals AGIO Stock Holding History

Advantage Investment Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,950	Closed	-$197K	–	997
2017 Q3	$197K	Sell	2,950 -300	-9%	-$18K	0.06%	173
2017 Q2	$167K	Hold	3,250	–	–	0.06%	180
2017 Q1	$190K	Buy	3,250 +1,700	+110%	+$81.5K	0.08%	150
2016 Q4	$65K	Hold	1,550	–	–	0.02%	283
2016 Q3	$82K	Buy	+1,550	New	+$67.5K	0.03%	246
2015 Q4	–	Sell	-287	Closed	-$20K	–	861
2015 Q3	$20K	Hold	287	–	–	0.01%	444
2015 Q2	$32K	Hold	287	–	–	0.02%	400
2015 Q1	$27K	Buy	+287	New	+$32.2K	0.02%	419

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Advantage Investment Management's AGIO Position: Q4 2017 in Review

Advantage Investment Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2017, closing a stake of 2,950 shares — an estimated $197K sold.

Advantage Investment Management first reported a position in AGIO in Q1 2015 and held it in 8 quarters. The position peaked at $197K in Q3 2017. 178 funds tracked by Wall St. Rank hold AGIO as of Q4 2017.

Advantage Investment Management reported no remaining Agios Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Advantage Investment Management sold 2,950 Agios Pharmaceuticals shares in Q4 2017, an estimated $197K.
Advantage Investment Management first reported a position in Agios Pharmaceuticals in Q1 2015 and held it in 8 quarters.
Advantage Investment Management's Agios Pharmaceuticals position peaked at $197K in Q3 2017.
178 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2017.

Based on Advantage Investment Management's 13F filing for Q4 2017, filed 12 Feb 2018.